ArticlePloS one2026
Targeted sequencing provides genetic insights into familial cardiovascular disease among young adults in a high consanguinity population.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular diseases (CVDs) account for approximately 19.8 million deaths annually, with coronary artery disease (CAD) as a major contributor. Genetic factors play an important role in CVD development. Genetic risk can be attributed to monogenic and polygenic risk variants. Patients with rare, Mendelian monogenic CVDs have been shown to have mutations in many causative genes, including LRP6, MEF2A, CYP27A1, and ST6GALNAC5.
methodsA case-control study was conducted at two tertiary care hospitals in Peshawar, Pakistan, Lady Reading Hospital and Peshawar Institute of Cardiology. The study included 20 patients with familial CVDs diagnosed through clinical and laboratory investigations and 20 matched healthy controls. Whole blood and relevant clinical-demographic data were collected, with matched control samples selected by age, gender, and family background, with minimizing variability to ensure accurate comparison. A total of 5 mL of blood was drawn from each patient and transported to the Molecular and Genomic Laboratory (IPDM) at Khyber Medical University. DNA was extracted from the collected samples, and targeted PCR and Sanger sequencing were performed. The sequencing data were analyzed using bioinformatics tools such as FinchTV and BioEdit.
resultsThe analysis demonstrated the presence of mutations in 12 out of 20 patient's DNA, including LRP6 gene variants (146344T > A in two patients, 146345A > G in three, and 92497C > A and 94776T > A in one each), MEF2A gene variants (113826A > T in one patient and 113802T > A in two), and CYP27A1 gene variants (5924G > C and 6016G > A in one patient each).
conclusionThis study identified genetic variants in the LRP6, MEF2A, and CYP27A1 genes among young patients with familial CVD using targeted PCR and Sanger sequencing. The detection of these variants in a proportion of cases suggests a possible genetic contribution within the studied cohort. However, further studies with larger sample sizes and advanced sequencing approaches (WGS/NGS) are required to confirm the clinical significance of these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.